Monte Rosa Therapeutics, Inc.
GLUE · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
Business Summary
1 Item 1A. Risk Factors 85 Item 1B. Unresolved Staff Comments 141 Item 1C. Cybersecurity 141 Item 2. Properties 141 Item 3. Legal Proceedings 142 Item 4. Mine Safety Disclosures 142 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 143 Item 6. [Reserved] 144 Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations 145 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 15...
Next Earnings
Q2 FY2026 — expected 2026-09-09
Key Facts from Earnings Calls
| Type | Subject | Detail | Quarter |
|---|
| topic_mention | GLUE | discussed_in_filing Cybersecurity | |
| topic_mention | GLUE | discussed_in_filing Cybersecurity | |
| topic_mention | GLUE | discussed_in_filing Cybersecurity | |
| topic_mention | GLUE | discussed_in_filing Cybersecurity | |
Annual Reports (10-K)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-109360 | EDGAR | 119K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042344 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031150 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008440 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004927 | EDGAR | — |
Quarterly Reports (10-Q)
| Filed | Period | Accession | Source | Full Text |
|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268045 | EDGAR | 26K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104550 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066372 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122780 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093296 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056288 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061995 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040959 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021201 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024447 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016844 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009324 | EDGAR | — |
Recent Current Reports (8-K)
| Filed | Accession | Source | Full Text |
|---|
| 2026-03-17 | 0001193125-26-109353 | EDGAR | 5K words |
| 2026-02-10 | 0001193125-26-044616 | EDGAR | — |
| 2026-01-09 | 0001193125-26-009005 | EDGAR | — |
| 2026-01-07 | 0001193125-26-006341 | EDGAR | — |
| 2026-01-07 | 0001193125-26-005420 | EDGAR | — |
| 2025-12-16 | 0001193125-25-319981 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268042 | EDGAR | — |
| 2025-09-15 | 0001193125-25-202760 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104545 | EDGAR | — |
| 2025-06-13 | 0000950170-25-086129 | EDGAR | — |
80 total filings indexed. 53 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
Sector Peers
Company Identity
| CIK | 0001826457 |
| Ticker | GLUE |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
Get More Data
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile
Stock Quote
AI Readiness Report
Origin Provenance
page leaf: 59c550d75493265a39e5ca07089ff53a302daeb9bf5ec2805cfabe35bd28cb41
parent: fe3e8abb4c578a501c57335e44e4c3450a30a59edb48342e49bd577f3353de93
content hash: 6d4b4c413d3007f29e3aa5d6d2e9b5aa771da9b5086768aa6c961e737a363798
signed: 2026-04-13T04:45:18.901Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf